Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00150449
NCT00150449CompletedPhase 3

A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders

Pfizer138 sites in 9 countries511 target enrollmentStarted: January 2001Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Pfizer
Enrollment
511
Locations
138
Primary Endpoint
Safety Tolerability
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Must have completed the double-blind portion of the preceding trial
  • •Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion Criteria

  • •Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.

Outcomes

Primary Outcomes

Safety Tolerability

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Pfizer
Sponsor Class
Industry

Study Sites (138)

Loading locations...

Similar Trials

Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral NeuropathyDiabetic Neuropathy, Painful
NCT00553280Pfizer's Upjohn has merged with Mylan to form Viatris Inc.123
Completed
Phase 3
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With FibromyalgiaFibromyalgia
NCT00830128Pfizer's Upjohn has merged with Mylan to form Viatris Inc.106
Completed
Phase 3
An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic PainSpinal Cord DiseasesSpinal Cord InjuriesNeuralgiaPain
NCT01202227Pfizer's Upjohn has merged with Mylan to form Viatris Inc.104
Completed
Phase 2
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.Epilepsy, Partial
NCT00141414Pfizer82
Completed
Phase 3
Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.Pain
NCT00141362Pfizer325